SCHEMBL2177600

SCHEMBL2177600

COc1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N([C@H](C(=O)O)C(C)C)C4)cc2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
GAA P10253 1/20 0.48
ATM Q13315 1/20 0.48
PLAU P00749 1/20 0.48
ABCB1 P08183 2/20 0.47
POLB P06746 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 3/20 0.46
USP2 O75604 1/20 0.46
NAMPT P43490 1/20 0.46
ITGB3 P05106 1/20 0.45
ITGA2B P08514 1/20 0.45
ITGA2 P17301 1/20 0.45
ALDH1A1 P00352 2/20 0.45
PKM P14618 2/20 0.45
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719003 1.00 KMT2A (0.49) KMT2AMEN1GAAATMPLAU
SCHEMBL2180708 0.93 GAA (0.48) KMT2AMEN1GAAATMPLAU
SCHEMBL13719207 0.91 GAA (0.50) KMT2AMEN1GAAABCB1POLB
SCHEMBL2179197 0.91 GAA (0.50) KMT2AMEN1GAAABCB1POLB
SCHEMBL2180067 0.89 TP53 (0.57) KMT2APLAUABCB1NPC1RAB9A
SCHEMBL2180197 0.89 TP53 (0.57) KMT2APLAUABCB1NPC1RAB9A
SCHEMBL2179095 0.87 LMNA (0.52) KMT2AMEN1ATMNPC1RAB9A
SCHEMBL2179226 0.87 LMNA (0.52) KMT2AMEN1ATMNPC1RAB9A
SCHEMBL2178118 0.87 LMNA (0.48) LMNATP53ITGB3ITGA2BITGA2
SCHEMBL13719015 0.87 LMNA (0.48) LMNATP53ITGB3ITGA2BITGA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT KMT2A 1705/4885MEN1 3071/4885GAA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.